New Frontier for Genomics: Radiotherapy in Early Breast Cancer

Terry P. Mamounas, MD, MPH; Melissa P. Mitchell, MD, PhD; and Wendy A. Woodward, MD, PhD
Published: Wednesday, Apr 08, 2020
Terry P. Mamounas, MD, MPH

Terry P. Mamounas, MD, MPH

In early-stage breast cancer, molecular subtyping and gene expression profiling has improved our ability to estimate risk of distant recurrence above and beyond traditional clinicopathologic factors and biomarkers.1-7 Despite this considerable progress in refining risk of distant recurrence, risk assessment for locoregional recurrence (LRR) is still primarily based on traditional clinicopathologic factors such as patient age, tumor size, grade, pathologic nodal status, presence of lymphovascular space invasion, and margin width.8,9
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication